Robotic Surgery Extends Benefits to Bladder Cancer Patients

	Tweet

Robotic surgery, largely pioneered for prostate cancer surgery, is rapidly being adapted for use in other areas, including for bladder cancer patients. Urologic surgeons at NewYork-Presbyterian Hospital/Weill Cornell Medical Center now have significant experience—and have demonstrated considerable success—with robotics for removal of the bladder, also known as cystectomy. Their findings are published in a recent edition of the peer-reviewed publication, the British Journal of Urology-International.

Led by NewYork-Presbyterian/Weill Cornell’s Dr. Douglas Scherr, the study shows that the robotic approach provides similar benefits to prostate resection, including dramatically faster recoveries with equal, or better, surgical precision. Specifically, robotic cystectomy patients have an average hospital stay of five days, compared with eight days for the standard open bladder surgery.

During the procedure, which makes use of Intuitive Surgical’s da Vinci® Surgical System, the surgeon makes five to six small incisions in the abdomen, through which surgical instruments and a tiny stereoscopic camera are inserted. Once the bladder is removed, the surgeon creates a new channel for urine to pass from the body.

"While we are only beginning to collect long-term empirical data for the bladder, there are early indications that the surgery is at least as good as open surgery at removing cancer,” says Dr. Scherr, who has performed more than 100 of the procedures—believed to be among the highest volume anywhere. “Our research found that patients treated with robotic surgery had just as good a cancer outcome as those individuals treated at the same center with traditional open surgery.”

“Robotics appears to be superior to the standard open technique in selected cases of bladder cancer, and based on results to date, there is every reason to expect the long-term data to show it to have advantages such as reduced recovery time,” adds Dr. Scherr, who is clinical director of urologic oncology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center and the Ronald Stanton Clinical Scholar in Urology and associate professor of urology at Weill Cornell Medical College.

Dr. Scherr and his team at NewYork-Presbyterian/Weill Cornell have transformed the care of bladder cancer patients by offering a comprehensive minimally invasive care program. They have been able to perform total urinary reconstruction with neobladders using the robotic approach. In addition, robotic surgery provides the precision necessary to perform a nerve-sparing operation so men can enjoy normal sexual function following surgery. Both men and women have shown great benefit from robotic surgery, which is evidenced by less need for blood transfusion, less pain, shorter hospital stay, improved return in bowel function, and an overall significant reduction in complications compared with the open approach.

Surgery is one part of a comprehensive treatment program for bladder cancer patients offered at NewYork-Presbyterian/Weill Cornell.

For more information, patients may call (866) NYP-NEWS.

NewYork-Presbyterian Hospital/Weill Cornell Medical Center
NewYork-Presbyterian Hospital/Weill Cornell Medical Center, located in New York City, is one of the leading academic medical centers in the world, comprising the teaching hospital NewYork-Presbyterian and Weill Cornell Medical College, the medical school of Cornell University. NewYork-Presbyterian/Weill Cornell provides state-of-the-art inpatient, ambulatory and preventive care in all areas of medicine, and is committed to excellence in patient care, education, research and community service.

Weill Cornell physician-scientists have been responsible for many medical advances—from the development of the Pap test for cervical cancer to the synthesis of penicillin, the first successful embryo-biopsy pregnancy and birth in the U.S., the first clinical trial for gene therapy for Parkinson’s disease, the first indication of bone marrow’s critical role in tumor growth, and, most recently, the world’s first successful use of deep brain stimulation to treat a minimally-conscious brain-injured patient. NewYork-Presbyterian, which is ranked sixth on the U.S.News & World Report list of top hospitals, also comprises NewYork-Presbyterian Hospital/Columbia University Medical Center, Morgan Stanley Children’s Hospital of NewYork-Presbyterian, NewYork-Presbyterian Hospital/Westchester Division and NewYork-Presbyterian Hospital/The Allen Pavilion. Weill Cornell Medical College is the first U.S. medical college to offer a medical degree overseas and maintains a strong global presence in Austria, Brazil, Haiti, Tanzania, Turkey and Qatar.

Source: NewYork-Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College

RELATED STORIES:
Survivors of Childhood Cancers Treated with Cyclophosphamide More Likely to Develop Bladder Cancer   Women in nursing homes often have bladder problems   Urinary tract cancer associated with Chinese herbal products containing aristolochic acid   Selenium May Prevent High Risk-Bladder Cancer   Delaying bladder cancer surgery increases mortality   Radiation does not improve survival for rare, invasive bladder cancer   Bladder cancer: A difficult problem?   Bladder cancer patients rarely receive recommended care   The Predictors of Local Recurrence After Radical Cystectomy in Patients with Invasive Bladder Cancer   Home urine testing cuts bladder cancer deaths   Nearly all patients with high-grade bladder cancer do not receive guideline-recommended care   More Intense Bladder Cancer Treatment Does Not Improve Survival   Thomas Jefferson University Hospital adopts new imaging agent to improve detection of bladder cancer   Variation in prostate stem cell antigen gene raises bladder cancer risk   Blood test may find markers of bladder cancer risk   Sales jobs tied to bladder cancer risk   AUA releases new guidelines on non-muscle invasive bladder cancer   Researcher Says Improved Detection of Bladder Tumors Reduces Cancer Recurrence   Protein Key to Bladder Cancer Spread, Potential Drug Target   Scientists find one reason why bladder cancer hits more men   Consumption of Cultured Milk Products May Reduce Bladder Cancer Risk   New Bladder Cancer Therapy for Patients Unresponsive to Standard Treatment

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]